Clinical trials: Locally Advanced Rectal Cancer
Locally Advanced Rectal Cancer
Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
The purpose of this study is to explore the efficacy and safety of involved-field radiotherapy-TNT combined with PD-1 inhibitors in pMMR locally advanced rectal cancer.
- Trial name
- NCT07057089
- Testing
- Capecitabine, Camrelizumab, CAPOX
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hebei Medical University Fourth Hospital
Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Efficacy and safety of short-course radiotherapy in total neoadjuvant therapy combined with enlonstobart for pMMR locally advanced rectal cancer
- Trial name
- NCT07448077
- Testing
- Experimental: short-course radiotherapy and immunotherapy, Chemoradiotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Locally Advanced Rectal Cancer (LARC)
To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR
To evaluate the pathological complete response rate (pCR) of intestinal flora transplantation combined with short-course radiotherapy +CAPOX+ sintilimab in neoadjuvant therapy for locally advanced rectal cancer (pMMR/MSS type)
- Trial name
- NCT07738042
- Testing
- Sintilimab, CAPOX (oxaliplatin/capecitabine), Short-course radiotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29
The aim of the ShorTrip trail is to evaluate the activity and the safety of total neoadjuvant strategy with FOLFOXIRI as consolidation therapy preceded by short-course radiotherapy and followed by surgery in LARC patients.
- Trial name
- ShorTrip (NCT05253846)
- Testing
- Irinotecan, Oxaliplatin, Lederfolin
- Where
- Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
This phase I trial studies the side effects and best dose of papaverine (PPV) when given together with radiation therapy (RT) and tests how well it works in treating patients with rectal cancer that has spread to nearby tissue or…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT06834126
- Testing
- Biospecimen Collection, Computed Tomography, Consolidation Therapy
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer
THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality for locally advanced rectal cancer (LARC), and patients achieving complete response (CR) generally have improved local control, metastasis-free…
- Conditions
- Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer, Pathological Complete Response
- Trial name
- THUNDER2 (NCT04815694)
- Testing
- RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Locally Advanced Rectal Cancer
Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence
The purpose of this study is to identify the most promising treatment sequence in total neoadjuvant therapy for locally advanced rectal cancer with a high risk of recurrence.
- Trial name
- ICONA (NCT05054959)
- Testing
- Consolidation CAPOX Chemotherapy, Induction CAPOX Chemotherapy
- Where
- Slovenia
- Volunteers
- 62 people
- Sponsor
- Institute of Oncology Ljubljana
Locally Advanced Rectal Cancer (LARC)
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
This is a single-center, open-label, single-arm clinical study aimed at conducting a preliminary evaluation of the efficacy and safety of combining PCSK9 inhibitors and PD-1 inhibitors (dual inhibitors) with neoadjuvant…
- Trial name
- NCT06933251
- Testing
- Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
Locally Advanced Rectal Cancer
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
This is an open-label, prospective phase II clinical trial to evaluate the therapeutic and prognostic implications of tumor immune microenvironment in the neoadjuvant immunotherapy combined with chemoradiotherapy for patients…
- Trial name
- TIMENT-R (NCT05507112)
- Testing
- PD-1 inhibitor, Capecitabine, Long-course radiation therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Rectal Adenocarcinoma, High-risk Locally Advanced
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
This study adopts a prospective randomized controlled design to evaluate the efficacy and safety of short-course radiotherapy followed by sequential PD-1 inhibitor and FOLFOX chemotherapy versus conventional regimens in high-risk…
- Conditions
- Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT), Immunotherapy
- Trial name
- STAR (NCT07669220)
- Testing
- Short-course Radiotherapy, SCRT, Toripalimab
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Mid-low Locally Advanced Rectal Cancer
rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer
This is a multi-center, randomized, phase II study, aimed to evaluate the efficacy of investigational product at a dose of 1800 µg/day when given in combination with TNT.
- Trial name
- rSIFN-co (NCT07662278)
- Testing
- Recombinant Super-Compound Interferon (rSIFN-co), Total Neo-adjuvant therapy
- Volunteers
- 90 people
- Sponsor
- Sichuan Huiyang Life Science and Technology Corporation
Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
The purpose of this study is to find out whether the combination of botensilimab and balstilimab (BOT/BAL) is a safe and effective treatment that causes few or mild side effects for people with mismatch repair proficient…
- Trial name
- NCT06843434
- Testing
- Balstilimab, Botensilimab
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Rectal Cancer
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer
This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery…
- Trial name
- IMPERIA (NCT07645118)
- Testing
- Nivolumab, HDRBET, Total Mesorectal Excision (TME)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Dr. Te Vuong
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
This early phase I trial investigates how well 64Cu-labeled M5A antibody scan works in assessing tumor activity before and after patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) who…
- Conditions
- Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8
- Trial name
- NCT05245786
- Testing
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Locally Advanced Rectal Cancer (LARC)
Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer
Standard treatment for patients with proficient mismatch repair (pMMR) / microsatellite stable (MSS) locally advanced rectal cancer (LARC) consists primarily of neoadjuvant chemoradiotherapy followed by radical surgery.
- Trial name
- NCT07581626
- Testing
- SCRT+targeted therapy+immunotherapy+chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Locally Advanced Rectal Cancer, Locally Recurrent Rectal Cancer
Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial
Single centre double-blinded three-arm randomised controlled trial of extended margin surgery + IOERT at standard dose (10 Gy) versus extended margin surgery + IOERT at higher dose (15 Gy) versus extended margin surgery alone in…
- Trial name
- ELECTRA (NCT05877352)
- Testing
- Intraoperative Electron Radiotherapy (IOERT), Extended Margin Surgery
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.
- Conditions
- Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, HER2 Positive Rectal Adenocarcinoma
- Trial name
- NCT05672524
- Testing
- Trastuzumab, Tucatinib
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Rectal Carcinoma
Preoperative, Adaptive Radiotherapy Concomitant to Chemotherapy for Rectal Adenocarcinoma (Adaptive Rectal Cancer Trial 02)
The aim of this clinical study is to increase the rate of pathological responses up to 70% by means of improved patient selection operated by a radiobiological index called ERI_TCP and by an increase in the dose of radiotherapy…
- Trial name
- NCT07580027
- Testing
- Preoperative, adaptive radiotherapy
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- IRCCS San Raffaele
Locally Advanced Resectable Rectal Cancer
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.
- Trial name
- NCT07454720
- Testing
- Adebrelimab in combination with SHR-8068 and chemotherapy, Adebrelimab combined with chemotherapy, Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 165 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Locally Advanced Rectal Cancer
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
phase II clinical trial to evaluate node-sparing short-course radiation combined with total neoadjuvant CAPOX and Sintilimab for MSS locally advanced rectal cancers.
- Trial name
- CASINOs (NCT06204094)
- Testing
- node-sparing short-course radiotherapy, Sintilimab, Capecitabine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Jinhua Central Hospital